Cadila Healthcare spurts on receiving USFDA approval for Phase I clinical trials of ‘ZYDPLA1’

23 Oct 2013 Evaluate

Cadila Healthcare is currently trading at Rs 671.00, up by 9.95 points or 1.51% from its previous closing of Rs 661.05 on the BSE.

The scrip opened at Rs 664.90 and has touched a high and low of Rs 677.95 and Rs 662.60 respectively. So far 13013 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 924.60 on 22-Feb-2013 and a 52 week low of Rs 631.00 on 20-Aug-2013.

Last one week high and low of the scrip stood at Rs 675.00 and Rs 655.00 respectively. The current market cap of the company is Rs 13737.60 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 14.71% and 10.50% respectively.

Cadila Healthcare, earlier known as Zydus Cadila, an innovative global pharmaceutical company, has received an approval for Phase I clinical trial from the USFDA for ZYDPLA1 - a next generation, long-acting DPP-4 Inhibitor. ZYDPLA1 is an orally active, small molecule NCE, discovered and developed by the Zydus Research Centre, the NCE research wing of Zydus.

ZYDPLA1 is a novel compound in the Gliptin class of anti-diabetic agents. It works by blocking the enzyme Dipeptidyl Peptidase-4 (DPP-4), which inactivate the Incretin hormone GLP-1.

Currently, all available DPP-4 inhibitors are dosed once-daily, ZYDPLA1 with a once-a-week dosing regimen, would provide diabetic patients with a more convenient treatment alternative, ZYDPLA1 will offer sustained action, which will result, in an improved efficacy profile.

Zydus Lifesciences Share Price

901.30 -2.70 (-0.30%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×